Overexpression of certain LSC antigens has been described in AML with specific genetic aberrations, for example, CD123 in AML with NPM1 mutation [17], CD47 in AML with CBFB::MYH11 fusion and AML with NPM1 mutation but not FLT3 ITD [113], and TIM3 in AML with RUNX1::RUNXT1 fusion, CBFB::MYH11 fusion, and CEBPA mutations [114]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.